Vitiligo News

ORLANDO — Outgoing American Academy of Dermatology President Seemal R. Desai, MD, FAAD, passed the torch to Susan C. Taylor, MD, FAAD, who said she will continue pushing efforts to unify the organization during “a time of great disruption.”

MIAMI BEACH, Fla. — When medical interventions fail, melanocyte keratinocyte transplantation may be the most advanced procedural option for vitiligo, according to a speaker at South Beach Symposium.

Individuals with vitiligo did not display a significantly increased risk for cancer compared with the general population, according to a study.

The Janus kinase inhibitor baricitinib, in combination with narrowband ultraviolet B therapy, improved vitiligo, according to a study.

Paramedical tattoos can be used for vitiligo by color matching tattoo ink with patients’ skin tones in vitiligo-affected areas, according to a presenter at the American Society for Dermatologic Surgery Annual Meeting.

An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

A study on cancer-causing benzene in acne products was Healio Dermatology’s most-read article of October, with coverage from clinical meetings also garnering attention.

ORLANDO — Autologous skin cell suspension using RECELL was an effective and safe treatment for patients with stable vitiligo, according to a presentation at the American Society for Dermatologic Surgery Annual Meeting.